News & Updates

Show Multimedia Only
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

04 Jan 2022 byAudrey Abella

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

04 Jan 2022